-
Mashup Score: 1Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV - 9 hour(s) ago
Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS - 1 month(s) ago
The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3European Commission Approves Frontline Luspatercept for Transfusion-Dependent Anemia in Lower-Risk MDS - 1 month(s) ago
The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN - 1 month(s) ago
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis - 1 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN - 1 month(s) ago
Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances - 1 month(s) ago
Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis - 1 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances - 1 month(s) ago
Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis - 1 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV @GhaithAbuZeinah @WeillCornell @BloodAdvances #mpnsm #oncology https://t.co/nApWh7RnYu